Imatinib is currently the treatment of choice of CML, but despite of the excellent results, it is not able to completely eradicate the disease and resistance may occur. The most studied mechanism is the presence of ABL kinase mutations that interfere with imatinib binding and action, gene amplification and clonal evolution. However, there are other mechanisms involved and less studied such as drug absorption and influx and efflux of imatinib. Besides the true causes of resistance, compliance is always a concern and also drug interaction should be checked. An understanding of these mechanisms will certainly contribute to develop new strategies for the treatment of resistant cases.30SUPPL. 12226Druker, B.J., Guilhot, F., OBrien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2006) N Engl J Med, 355 (23), pp. 2408-2417Hochhaus, A., Hughes, T., Clinical resistance to imatinib: Mechanisms and implications (2004) Hematol Oncol Clin North Am, 18, pp. 641-656Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet (2006) Blood, 108 (6), pp. 1809-1820Shah, N.P., (2005) Loss of response to imatinib: Mechanisms and management, pp. 183-187. , Hematology Am Soc Hematol Educ ProgramDruker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M., Goldman, J.M., (2001) Chronic myelogenous leukemia, pp. 87-112. , Hematology Am Soc Hematol Educ ProgramKantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia (2002) N Engl J Med, 346 (9), pp. 645-652Ottmann, O.G., Druker, B.J., Sawyers, C.L., Goldman, J.M., Reiffers, J., Silver, R.T., A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias (2002) Blood, 100 (6), pp. 1965-1971Part, A.J.F., I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia (2007) Lancet Oncol, 8 (11), pp. 1018-1029Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.A., Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia (2007) Blood, 109 (8), pp. 3496-3499Larson, R., Druker, B.J., Guilhot, F., OBrien, S., Riviere, G.J., Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: A subanalysis of IRIS study (2008) Blood, , DOI 10.1182/blood-2007-10-116475Marin, D., Marktel, S., Bua, M., Armstrong, L., Goldman, J.M., Apperley, J.F., The use of imatinib (STI571) in chronic myelod leukemia: Some practical considerations (2002) Haematologica, 87 (9), pp. 979-988Thomas, J., Wang, L., Clark, R.E., Pirmohamed, M., Active transport of imatinib into and out of cells: Implications for drug resistance (2004) Blood, 104 (12), pp. 3739-3745White, D.L., Saunders, V.A., Dang, P., Engler, J., Venables, A., Zrim, S., Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity (2007) Blood, 110 (12), pp. 4064-4072Kantarjian, H., Talpaz, M., OBrien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (2004) Blood, 103 (8), pp. 2873-2878Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification (2001) Science, 293 (5531), pp. 876-880Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia (2002) Cancer Cell, 2 (2), pp. 117-125Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance (2002) Blood, 99 (9), pp. 3472-3475Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the Gimema Working Party on Chronic Myeloid Leukemia (2006) Clin Cancer Res, 12 (24), pp. 7374-7379Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., Kuriyan, J., Structural mechanism for STI-571 inhibition of abelson tyrosine kinase (2000) Science, 289 (5486), pp. 1938-1942Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) (2002) Cancer Res, 62 (15), pp. 4236-4243Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis (2003) Blood, 102 (1), pp. 276-283Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the Gimema Working Party on Chronic Myeloid Leukemia (2005) J Clin Oncol, 23 (18), pp. 4100-4109Nicolini, F.E., Corm, S., Le, Q.H., Sorel, N., Hayette, S., Bories, D., Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(phi)-LMC Group) (2006) Leukemia, 20 (6), pp. 1061-1066Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., OBrien, S., Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (2006) Leukemia, 20 (10), pp. 1767-1773Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results (2006) Blood, 108 (1), pp. 28-37Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib (2004) Clin Chem, 50 (7), pp. 1205-1213Ernst, T., Erben, P., Muller, M.C., Paschka, P., Schenk, T., Hoffmann, J., Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib (2008) Haematologica, 93 (2), pp. 186-192Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J.L., Philippe, N., Facon, T., Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment (2002) Blood, 100 (3), pp. 1014-1018Willis, S.G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy (2005) Blood, 106 (6), pp. 2128-2137Khorashad, J.S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib (2006) Leukemia, 20 (4), pp. 658-663Chu, S., Xu, H., Shah, N.P., Snyder, D.S., Forman, S.J., Sawyers, C.L., Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment (2005) Blood, 105 (5), pp. 2093-2098Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain (2007) Haematologica, 92 (3), pp. 401-404Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood. 200815:111(4):2378-81. Epub Nov. 2007Shah, N.P., Skaggs, B.J., Branford, S., Hughes, T.P., Nicoll, J.M., Paquette, R.L., Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency (2007) J Clin Invest, 117 (9), pp. 2562-2569Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007) Blood, 110 (10), pp. 3540-3546OHare, T., Eide, C.A., Deininger, M.W., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia (2007) Blood, 110 (7), pp. 2242-2249Griswold, I.J., MacPartlin, M., Bumm, T., Goss, V.L., OHare, T., Lee, K.A., Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib (2006) Mol Cell Biol, 6 (16), pp. 6082-6093Branford, S., Rudzki, Z., Parkinson, I., Grigg, A., Taylor, K., Seymour, J.F., Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations (2004) Blood, 104 (9), pp. 2926-2932Wang, L., Knight, K., Lucas, C., Clark, R.E., The role of serial BCRABL transcript monitoring in predicting the emergence of BCRABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia (2006) Haematologica, 91 (2), pp. 235-239Cortes, J., Talpaz, M., O'Brien, S., Jones, D., Luthra, R., Shan, J., Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate (2005) Clin Cancer Res, 11 (9), pp. 3425-3432Press, R.D., Love, Z., Tronnes, A.A., Yang, R., Tran, T., Mongoue-Tchokote, S., BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML (2006) Blood, 107 (11), pp. 4250-4256Hochhaus, A., Kreil, S., Corbin, A.S., La Rosee, P., Muller, M.C., Lahaye, T., Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (2002) Leukemia, 16 (11), pp. 2190-2196Marktel, S., Marin, D., Foot, N., Szydlo, R., Bua, M., Karadimitris, A., Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression (2003) Haematologica, 88 (3), pp. 260-267Deininger, M.W., Cortes, J., Paquette, R., Park, B., Hochhaus, A., Baccarani, M., The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells (2007) Cancer, 110 (7), pp. 1509-1519Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L., Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro (2002) Blood, 99 (1), pp. 319-325Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment (2003) Blood, 101 (12), pp. 4701-4707Mahon, F.X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models (2003) Blood, 101 (6), pp. 2368-2373Widmer, N., Colombo, S., Buclin, T., Decosterd, L.A., Functional consequence of MDR1 expression on imatinib intracellular concentrations (2003) Blood, 102 (3), p. 1142Ferrao, P.T., Frost, M.J., Siah, S.P., Ashman, L.K., Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro (2003) Blood, 102 (13), pp. 4499-4503Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 (2003) Blood, 101 (2), pp. 690-698Dai, Y., Rahmani, M., Corey, S.J., Dent, P., Grant, S., A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 (2004) J Biol Chem, 279 (33), pp. 34227-34239